Neoadjuvant therapy is widely recognised as an effective treatment option for locally advanced breast cancer of any subtype, as well as early-stage HER2-positive (HER2+) and triple-negative breast cancer (TNBC). The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.